<PAGE>
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
Dated September 15, 1999
PHOENIX INTERNATIONAL LIFE SCIENCES INC.
----------------------------------------
(Translation of registrant's name into English)
2350 Cohen Street
-----------------
Saint Laurent, Quebec Canada H4R 2N6
------------------------------------
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F Form 40-F X (commenced in calendar
----- ----- year 1998)
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.
Yes No X
----- -----
If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): ______________
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
PHOENIX INTERNATIONAL LIFE SCIENCES INC.
----------------------------------------
(Registrant)
Date: September 15, 1999 By: /s/ David Moszkowski
------------------- ---------------------
David Moszkowski
Senior Vice President and
Chief Financial Officer
<PAGE>
EXHIBIT 99.1
FOR IMMEDIATE RELEASE
PHOENIX INTERNATIONAL LIFE SCIENCES INC. TO ANNOUNCE THE
--------------------------------------------------------
APPOINTMENT OF A NEW CHIEF EXECUTIVE OFFICER
--------------------------------------------
MONTREAL, AUGUST 31, 1999. Phoenix International Life Sciences Inc. is pleased
to announce the appointment of a new Chief Executive Officer, replacing Dr. John
W. Hooper.
This appointment follows a successful executive search for Dr. Hooper's
replacement after he announced plans to step down as CEO of Phoenix
International last spring. These changes take effect immediately.
At a special Board meeting today, company directors approved the appointment of
Phoenix International Life Sciences' new Chief Executive Officer. A separate
announcement, with more details, will be released very shortly.
The Board also approved the appointment of Mr. Claude E. Forget as the new
Chairman of the Board to replace Dr. Hooper who will remain a Director of the
Board. Mr. Forget has been a Director of Phoenix since 1989. Mr. Forget has held
numerous executive roles in both the private and public sectors in Quebec. He is
an Officer of the Order of Canada.
The members of the Board would like to express their thanks to Dr. John W.
Hooper who founded and has served this company with tremendous energy and
devotion during so many years and whose vision has inspired the current
positioning of the company.
Phoenix International Life Sciences Inc. is one of the largest pharmaceutical
contract research organizations with over two thousand employees worlwide.
This release contains "forward-looking" statements regarding future results and
events, including statements regarding expected future revenues, earnings and
growth rates and goals and operating plans of management. Phoenix's actual
future results may differ significantly from the results discussed in the
forward-looking statements contained in this release. Factors that may cause
such a difference include, but are not limited to: the inability of Phoenix to
win new business at the levels required; the cancellation or delay of contracts;
risks associated with the management of growth and the ability to attract and
retain employees; risks of integrating newly acquired businesses; competition;
any claims for patent infringement; unanticipated costs in connection with Year
2000 conversion; the ability to obtain future financing; adverse regulatory
developments; foreign exchange rate fluctuations; and uncertainty surrounding
the Euro.
For more information please contact:
David Moszkowski, Senior Vice-President and Chief Financial Officer
(514) 333-0033
<PAGE>
EXHIBIT 99.2
FOR IMMEDIATE RELEASE
NEWS RELEASE
------------
PHOENIX INTERNATIONAL ANNOUNCES APPOINTMENT
-------------------------------------------
OF NEW CHIEF EXECUTIVE OFFICER
------------------------------
MONTREAL, QUEBEC - SEPTEMBER 7, 1999 - The Board of Directors of Phoenix
International Life Sciences Inc. (NASDAQ: PHXI); (TSE/ME: PHX) announced the
appointment of Ian Lennox as Chief Executive Officer. The appointment of Mr.
Lennox follows the departure of Dr. John W. Hooper as Chairman and CEO,
announced last week.
"Ian brings to Phoenix strong international experience in the pharmaceutical and
life sciences industries, and has a record of building companies to create
value," said Claude Forget, Chairman of Phoenix International. "We are confident
that Ian will successfully lead Phoenix's growth into the next century."
"Phoenix International has grown rapidly through acquisitions over the past two
years, and I will be working with management to effectively integrate these
acquisitions and thereby build a solid base for accelerating growth" said Ian
Lennox. "The Company has the advantage of a strong customer focus and an
excellent reputation in all its markets."
Mr. Lennox was previously President and Chief Executive Officer of Toronto-based
Drug Royalty Corporation. During his tenure at Drug Royalty, Mr. Lennox led the
Company through a period of significant change in strategy and positioned the
Company for improved growth.
Prior to his appointment as Drug Royalty's President and CEO in 1997, Mr. Lennox
held a number of successive management positions in the United States and Latin
America with Monsanto Company, leading to his appointment as President and Chief
Executive Officer of Monsanto Company (Canada) Inc. in 1991. As President and
CEO of Monsanto Canada, Mr. Lennox managed a diverse portfolio of businesses
including pharmaceuticals, agricultural chemicals, and an emerging biotechnology
presence, that generated consolidated revenues in excess of $500 million. Mr.
Lennox is a Director of several international companies and is Chairman of Drug
Royalty Corporation. He holds a major degree in physiology and pharmacology, an
MBA from the University of Western Ontario, and has studied advanced business
management at Columbia Business School in New York.
Phoenix International Life Sciences Inc. is one of the largest pharmaceutical
contract research organizations with over two thousand employees worldwide.
This release contains "forward-looking" statements regarding future results
and events, including statements regarding expected future revenues, earnings
and growth rates and goals and operating plans of management. Phoenix's
actual future results may differ significantly from the results
<PAGE>
discussed in the forward-looking statements contained in this
release. Factors that may cause such a difference include, but are not limited
to: the inability of Phoenix to win new business at the levels required; the
cancellation or delay of contracts; risks associated with the management of
growth and the ability to attract and retain employees; risks of integrating
newly acquired businesses; competition; any claims for patent infringement;
unanticipated costs in connection with Year 2000 conversion; the ability to
obtain future financing; adverse regulatory developments; foreign exchange rate
fluctuations; and uncertainty surrounding the Euro.
FOR MORE INFORMATION, PLEASE CONTACT:
ANALYST CONTACT:
DAVID MOSZKOWSKI, C.A.
Senior Vice President and Chief Financial Officer
Phoenix International Life Sciences Inc.
Tel: (514) 333-0033 Fax: (514) 335-8351
E-mail: [email protected]
MEDIA CONTACT:
RICHARD GAREAU
Director of Communications
Phoenix International Life Sciences Inc.
Tel: (514) 333-0033 Fax: (514) 335-8351
E-mail: [email protected]
